Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2009

View Archived Issues

GeoVax requests pre-IND meeting with FDA for therapeutic AIDS vaccine

Chugai is granted additional approvals in China for Xeloda and Avastin

EMEA accepts for review Pharming's MAA for Rhucin for hereditary angioedema

2009 influenza A (H1N1) vaccine generates immune response in children

Alimera Sciences starts pilot study of Iluvien in patients with macular edema

Alizyme provides update on sale of Cetilistat

BioSante and Cell Genesys confirm final exchange ratio for merger

Nifurtimox/eflornithine combination therapy for sleeping sickness now available

Pluristem Therapeutics doses first patient in phase I trial for PAD

Protalix Biotherapeutics presents preclinical data on pr-anti-TNF for arthritis

Sangamo BioSciences plans to initiate second CCR5-ZFP trial in HIV/AIDS

TGen commences clinical trials for OSI-906 for adrenocortical carcinoma

Icagen initiates proof-of-concept study of ICA-105665 in photosensitive epilepsy

E.C. grants Gilead Sciences conditional marketing approval for Cayston

ASP-2151 inhibits VZV and HSV-1/-2 activity in vitro and reduces HSV-1 pathology in vivo

Shionogi and GSK report data from phase II trials of HIV integrase inhibitor S/GSK-1349572

ZT-031 shows favorable PK as intranasal formulation in preclinical evaluation

4SC-201 shows favorable oral profile and tolerability in patients with solid tumors

BIIB-022 shown to be safe in phase I trial in relapsed/refractory solid tumor patients

NicOx discovers NO donors for the treatment of hypertension and other conditions

HDAC inhibitors for the treatment of cancer presented by Roche

Boehringer Ingelheim claims BK1 receptor antagonists as analgesics

Cycloindole derivatives for the treatment of HCV infection described by iTherX

Cephalon discloses histamine H3 antagonists for the treatment of sleep disorders

NicOx submits NDA to FDA for naproxcinod in osteoarthritis

FDA grants accelerated approval to Allos Therapeutics' Folotyn for relapsed or refractory PTCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...